Steven K H Foung
Overview
Explore the profile of Steven K H Foung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
2719
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wrensch F, Keck Z, Foung S, Baumert T
J Hepatol
. 2019 Apr;
71(1):9-11.
PMID: 30992137
No abstract available.
12.
Urbanowicz R, Wang R, Schiel J, Keck Z, Kerzic M, Lau P, et al.
J Virol
. 2019 Jan;
93(7).
PMID: 30651366
The development of a prophylactic vaccine for hepatitis C virus (HCV) remains a global health challenge. Cumulative evidence supports the importance of antibodies targeting the HCV E2 envelope glycoprotein to...
13.
Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel M, et al.
Antiviral Res
. 2019 Jan;
162:136-141.
PMID: 30599173
Despite the development of direct-acting antivirals (DAAs), hepatitis C virus (HCV) infection remains a major cause for liver disease and cancer worldwide. Entry inhibitors block virus host cell entry and,...
14.
Bailey J, Urbanowicz R, Ball J, Law M, Foung S
Methods Mol Biol
. 2018 Dec;
1911:441-450.
PMID: 30593644
Hepatitis C virus (HCV) pseudoparticles (HCVpp) are generated by cotransfection of HCV envelope (E1 and E2) genes along with a retroviral packaging/reporter construct into HEK293T cells. Enveloped particles bearing HCV...
15.
Keck Z, Wang Y, Lau P, Foung S
Methods Mol Biol
. 2018 Dec;
1911:395-419.
PMID: 30593641
Yeast surface display (YSD) enables efficient screening and selection of single chain variable fragments (scFvs) of heavy (V) and light (V) chains that bind to target antigen with different affinities....
16.
17.
Wrensch F, Crouchet E, Ligat G, Zeisel M, Keck Z, Foung S, et al.
Front Immunol
. 2018 Jul;
9:1436.
PMID: 29977246
With more than 71 million people chronically infected, hepatitis C virus (HCV) is one of the leading causes of liver disease and hepatocellular carcinoma. While efficient antiviral therapies have entered...
18.
Keck M, Wrensch F, Pierce B, Baumert T, Foung S
Front Immunol
. 2018 Jun;
9:1194.
PMID: 29904384
Hepatitis C virus (HCV) continues to spread worldwide with an annual increase of 1.75 million new infections. The number of HCV cases in the U.S. is now greater than the...
19.
Fuerst T, Pierce B, Keck Z, Foung S
Front Microbiol
. 2018 Jan;
8:2692.
PMID: 29379486
The ability to use structure-based design and engineering to control the molecular shape and reactivity of an immunogen to induce protective responses shows great promise, along with corresponding advancements in...
20.
Mesalam A, Desombere I, Farhoudi A, Van Houtte F, Verhoye L, Ball J, et al.
Virology
. 2017 Nov;
514:30-41.
PMID: 29128754
Monoclonal antibodies (mAbs) targeting the hepatitis C virus (HCV) envelope have been raised mainly against envelope protein 2 (E2), while the antigenic epitopes of envelope protein 1 (E1) are not...